RESEARCH-USE BIOSIMILAR ANTIBODY
Samrotamab
Antibody-drug conjugate · IgG1
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric monoclonal antibody targeting LRRC15, with a Kd of 5.42 nM for human LRRC15. Samrotamab can be used to synthesize antibody-drug conjugates (ADC). Samrotamab disrupts the LRRC15-SCG5 signaling module, binds to a membrane-proximal conformational epitope within the C-terminal leucine-rich repeat region of LRRC15, and binds to the lateral edge of the LRR solenoid while leaving the canonical concave β-sheet surface fully exposed. Samrotamab reduces the viability of bladder cancer cells, inhibits clonogenic growth, impairs cell migration, and compromises cell invasion. Samrotamab induces compensatory upregulation of LRRC15 transcripts while suppressing the expression of SCG5 mRNA. Samrotamab is applicable to research related to urothelial carcinoma, sarcoma, osteosarcoma, and undifferentiated pleomorphic sarcoma.
PRODUCT OVERVIEW
A research-use configuration for comparative antibody studies
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric monoclonal antibody targeting LRRC15, with a Kd of 5.42 nM for human LRRC15. Samrotamab can be used to synthesize antibody-drug conjugates (ADC). Samrotamab disrupts the LRRC15-SCG5 signaling module, binds to a membrane-proximal conformational epitope within the C-terminal leucine-rich repeat region of LRRC15, and binds to the lateral edge of the LRR solenoid while leaving the canonical concave β-sheet surface fully exposed. Samrotamab reduces the viability of bladder cancer cells, inhibits clonogenic growth, impairs cell migration, and compromises cell invasion. Samrotamab induces compensatory upregulation of LRRC15 transcripts while suppressing the expression of SCG5 mRNA. Samrotamab is applicable to research related to urothelial carcinoma, sarcoma, osteosarcoma, and undifferentiated pleomorphic sarcoma.
Samrotamab is a recombinant research-use antibody directed against LRRC15.